Eradication therapy for<i>Burkholderia cepacia</i>complex in people with cystic fibrosis

Regan, Kate; Bhatt, Jayesh

doi:10.1002/14651858.cd009876

Cited by 6 publications

(3 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…, which found no articles to include in the study, there is a lack of evidence supporting treatment regimens for these important pathogens, which is reflected in the European Cystic Fibrosis Society (ECFS) guidelines. 3 73 In the following section, suggested strategies for the management of Achromobacter spp. , Burkholderia spp.…”

Section: Recommendations For the Management Of Other Cystic Fibrosis ...mentioning

confidence: 99%

“…It has been proposed that the overall strategy used in the management of P. aeruginosa lung infection, that is, aggressive eradication and maintenance therapy when this fails, may be applied in the treatment of other pathogenic gram negatives. 3 73 74…”

Section: Recommendations For the Management Of Other Cystic Fibrosis ...mentioning

confidence: 99%

“…Although no trials investigating eradication protocols for Burkholderia spp. were included in a Cochrane review, 73 a few trials have described protocols in a non-RCT setting. A small, retrospective study showed that eradication of Burkholderia is possible with 100% clearance in six patients after 1-year follow up.…”

Section: Recommendations For the Management Of Other Cystic Fibrosis ...mentioning

confidence: 99%

See 2 more Smart Citations

Antimicrobial Strategies for Cystic Fibrosis

Møller

Pressler

Qvist

2022

Semin Respir Crit Care Med

View full text Add to dashboard Cite

Lung infection is the leading cause of death in cystic fibrosis (CF), and antimicrobial therapies are the backbone of infection management. While many different strategies may be applied, rigorous microbiological surveillance, intensive eradication therapy, and long-term maintenance therapy based on inhaled antibiotics may be considered the main strategy for infection control in individuals with CF. While most of the existing evidence is based on infection with Pseudomonas aeruginosa, other important pathogens causing lung inflammation and deterioration exist and should be treated despite the evidence gap. In this chapter, we describe the approaches to the antimicrobial treatment of the most important pathogens in CF and the evidence behind.

show abstract

Section: Recommendations For the Management Of Other Cystic Fibrosis ...mentioning

confidence: 99%